A Curcumin-Nanosized Invasome Topical Formulation Evaluated Against Bacillus Subtilis Salmonella Bongori

Abstract

Curcumin is a natural product that is applied to treat a broad range of human diseases, such as airway infections and inflammation. Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities. Due to these properties, curcumin has been investigated for the treatment and supportive care of a variety of clinical conditions, including proteinuria, breast cancer, multiple myeloma, depression, and non-small cell lung cancer (NSCLC). Despite its proven efficacy against numerous experimental models, poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination have been shown to limit the therapeutic efficacy of curcumin. The current research is designed to explore the effect of a nanoscale invasome topical formulation of curcumin against Bacillus subtilis and Salmonella bongori. The antibacterial interest of the invasomal gel was assayed to determine a zone of inhibition towards distinct bacteria. The disc diffusion method was used to perform antimicrobial activities at three distinct awareness levels—25, 50, and 100 l/disc. indicated that the formula displayed a variable degree of antimicrobial activity in various strains. The inhibitory effect boomed with the increase in invasomal gel formula awareness from 50 to 100 l/disc. Bacillus subtilis was the most effective strain, with the strongest inhibition zone (8.6  0.754 to 14.7  0.374 mm), followed by Salmonella bongori (9.46  0.680 to 15.02  0.347 mm).